A 1-year, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of CP 945598 in the treatment of overweight, oral agent-treated subjects with type 2 diabetes mellitus
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Otenabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 07 Nov 2012 Biomarkers information updated
- 03 Nov 2009 Actual patient number (975) added, additional trial locations added as reported by ClinicalTrials.gov.
- 23 Dec 2008 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.